Boston Scientific shares retreated after the medical device manufacturer lowered its growth outlook. The company cited the lingering impact of a recent cybersecurity breach alongside an anticipated dip in fourth-quarter sales as primary drivers for the revision. Conversely, the online pharmacy Hims saw its stock rally sharply following a directive from Health Secretary Robert F. Kennedy Jr. By signaling that the administration would suspend enforcement against certain unapproved peptides, Kennedy bypassed traditional Food and Drug Administration protocols, igniting investor optimism regarding the firm’s product pipeline.

Biotech player Biogen faced a more complex quarter, reporting a transition to a net loss driven by elevated expenses, despite maintaining steady sales growth. Meanwhile, the sector faces increased scrutiny from the Labor Department. New federal regulations now require pharmacy-benefit managers to disclose granular pricing data to employer clients, including specific details on payments received from drug manufacturers. This push for transparency marks a significant shift in how intermediaries interact with the pharmaceutical supply chain.